Want to join the conversation?
For 2Q16, $EA's non-GAAP operating expenses were $479MM, down $18MM YoverY driven by FX. The improvement on guidance was driven by phasing and continued cost control. At constant currency, OpEx would have been up aprpox. $16MM, sharply driven by increased investment in R&D.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.